Free tool
FAERS Monitor: Talicia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213004 or its brand name (Talicia, Amoxicillin, Omeprazole Magnesium, Rifabutin). Reports on generic versions are filed under their own applications.
Reports
219
Serious
30
14% of reports
Hospitalization
10
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective32
- rash25
- treatment failure21
- headache18
- nausea18
- diarrhoea16
- fatigue16
- pain11
- vomiting11
- abdominal pain10
- dizziness10
- pruritus9
- abdominal pain upper8
- dyspepsia8
- pyrexia8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 17 |
| 2021 | 56 |
| 2022 | 50 |
| 2023 | 52 |
| 2024 | 26 |
| 2025 | 16 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,940 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| treatment failureSignal | 21 | 24.4 | 16.2 | 449 |
| dyspepsiaSignal | 8 | 7.8 | 4.0 | 41 |
| rashSignal | 25 | 5.5 | 3.8 | 90 |
| abdominal painSignal | 10 | 4.1 | 2.3 | 21 |
| abdominal pain upperSignal | 8 | 3.7 | 1.9 | 14 |
| headacheSignal | 18 | 2.8 | 1.8 | 19 |
| diarrhoeaSignal | 16 | 2.4 | 1.5 | 12 |
| drug ineffectiveSignal | 32 | 2.3 | 1.7 | 25 |
| pruritusSignal | 9 | 2.2 | 1.2 | 5 |
| vomitingSignal | 11 | 2.2 | 1.3 | 7 |
| pyrexiaSignal | 8 | 2.2 | 1.1 | 4 |
| nauseaSignal | 18 | 2.2 | 1.4 | 11 |
| fatigue | 16 | 2.0 | 1.2 | 7 |
| dizziness | 10 | 1.9 | 1.1 | 4 |
| pain | 11 | 1.7 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.